SCHEDULE: Rosalind Group Discloses 9.9% Stake in Biofrontera Inc.

Rosalind Advisors, Steven Salamon, Gilad Aharon, and Rosalind Master Fund L.P. jointly report a 9.9% beneficial ownership in Biofrontera Inc. common shares.

Summary

• Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon have filed an Amendment No. 7 to Schedule 13G for Biofrontera Inc.
• The reporting group beneficially owns 16,777,017 shares of Biofrontera Inc. Common Stock, representing 9.9% of the class.
• This aggregate amount includes 1,140,764 shares of Common Stock, 12,828,452 shares issuable upon exercise of preferred shares, and 2,807,801 shares issuable upon exercise of convertible debt.
• A 'blocker provision' prevents the holders from exercising preferred shares or convertible debt if it would result in beneficial ownership exceeding 9.99% of the Common Stock.
• Consequently, as of the event date, the reporting persons were unable to exercise the preferred shares or convertible debt due to these blockers.
• The percentage of class is calculated based on 11,423,323 common stock outstanding as of September 23, 2025.
• The securities were acquired and are held in the ordinary course of business, not for changing or influencing control, except for activities related to a nomination under Rule 240.14a-11.

Sentiment

Score: 6

Explanation: The filing is a standard disclosure of beneficial ownership. The significant stake held by the Rosalind group could be seen as a positive signal of investor confidence, but the blocker provision on a large portion of potential shares introduces a slight complexity, preventing a higher score.

Positives

• The reporting persons hold a significant stake (9.9%), indicating a substantial investment and potential long-term interest in Biofrontera Inc.
• The filing explicitly states the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control, which can signal stability and a passive investment approach.

Negatives

• A 'blocker provision' limits the immediate exercisability of a large portion of the potential ownership (12,828,452 preferred shares and 2,807,801 convertible debt shares), restricting the reporting persons' ability to fully convert these instruments if it would result in beneficial ownership exceeding 9.99%.

Risks

• The 'blocker provision' limits the ability of Rosalind Master Fund L.P. and related parties to convert preferred shares and convertible debt into common stock if it would result in beneficial ownership exceeding 9.99%. This could impact their liquidity or strategic flexibility.
• The existence of a large number of preferred shares (12,828,452) and convertible debt (2,807,801 shares) that could be converted into common stock, if the blocker provision is no longer applicable or ownership falls below the threshold, poses a potential future dilution risk for existing common shareholders.

Future Outlook

The filing does not provide forward-looking statements or guidance regarding Biofrontera Inc.'s future performance or strategic direction.

Industry Context

This filing is a routine disclosure of significant ownership by an investment group in a publicly traded company. It does not provide specific industry-related insights beyond the fact that Biofrontera Inc. operates in an industry where such investment structures (preferred shares, convertible debt) are utilized.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake (9.9%) could be viewed positively, signaling investor confidence. However, the potential for future dilution from preferred shares and convertible debt (if blockers are removed or ownership falls below 9.99%) remains a factor.

Key Dates

Recommendation

The filing indicates a significant institutional stake in Biofrontera Inc. by the Rosalind group, which could be a positive signal of long-term interest. However, the 'blocker provision' limits the immediate exercisability of a large portion of their potential ownership (preferred shares and convertible debt), preventing them from exceeding 9.99% beneficial ownership. This introduces uncertainty regarding the timing and impact of potential future conversions. While the current stake is substantial, the limitations on full conversion suggest a 'hold' position until there is more clarity on the future exercise of these convertible instruments and their potential dilutive effects.

Keywords

Biofrontera Inc., Rosalind Advisors, Schedule 13G, Beneficial Ownership, Common Shares, Preferred Shares, Convertible Debt, Blocker Provision, SEC Filing, Investment Advisor, Institutional Ownership